News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|April 20, 2016

Professional Expectations for Future

Episodes in this series

EP. 1 Types of Multiple Myeloma

EP. 1 Types of Multiple Myeloma

EP. 2 Testing Procedures and Considerations

EP. 2 Testing Procedures and Considerations

EP. 3 Considerations For Treatment

EP. 3 Considerations For Treatment

EP. 4 Monitoring Patients

EP. 4 Monitoring Patients

EP. 5 Top Considerations for Maintenance Therapy

EP. 5 Top Considerations for Maintenance Therapy

EP. 6 New Drug Classes For Treatment

EP. 6 New Drug Classes For Treatment

EP. 7 Clinical Trials and Stem Cell Transplants

EP. 7 Clinical Trials and Stem Cell Transplants

EP. 8 Professional Expectations for Future

EP. 8 Professional Expectations for Future

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL: © stock.adobe.com.

Jaypirca Significantly Improves PFS Outcomes in Untreated CLL/SLL

BySabrina Serani

December 9th 2025

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Breaking Down the Prostate Cancer Treatment Renaissance

December 9th 2025

Lore Gruenbaum

Insights Into What’s New in Blood Cancer Care

December 8th 2025

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

Epkinly Plus Chemo Elicits Durable Responses in DLBCL

ByDr. Josh Brody

December 8th 2025

Zervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

Zervyteg Shows Strong Responses in Acute Graft-Versus-Host Disease

ByAndrea Eleazar, MHS

December 8th 2025

Trending on CURE

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

Epkinly Plus Chemo Elicits Durable Responses in DLBCL

Insights Into What’s New in Blood Cancer Care

First Annual Blood Cancer Heroes Honors Leaders, Advocates and Survivors

© 2025 MJH Life Sciences^®

All rights reserved.